Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation

Laboratory Investigation

Volumn 80, Issue 7, 2000, Pages 1101-1110

  Sousa, Mónica Mendes ^c   Yan, Shi Du ^a   Stern, David ^a   Saraiva, Maria João ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF PORTO   (Portugal)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PREALBUMIN;

AMYLOID NEUROPATHY; ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; TRANSCRIPTION REGULATION;

EID: 0342646984     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3780116     Document Type: Article

References (42)

1. Almeida MR, Damas AM, Lans MC, Brouwer A, and Saraiva MJ (1997). Thyroxine binding to transthyretin Met 119. Comparative studies of different heterozygotic carriers and structural analysis. Endocrine 6:309-315.
2. Ando Y, Nyhlin N, Suhr O, Holmgren G, Uchida K, el Sahly M, Yamashita T, Terasaki H, Nakamura M, Uchino M, and Ando M (1997). Oxidative stress is found in amyloid deposits in systemic amyloidosis. Biochem Biophys Res Commun 232: 497-502.
3. Behl C, Davis J, Lesley R, and Schubert D (1994). Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77:817-827.
4. Blake CCF, Geisow MJ, Swan ID, Rerat C, and Rerat B (1974). Structure of human plasma prealbumin at 2-5 A resolution. A preliminary report on the polypeptide chain conformation, quaternary structure and thyroxine binding. J Mol Biol 88:1-12.
5. Boland K, Behrens M, Choi D, Manias K, and Perlmutter DH (1996). The serpin-enzyme complex receptor recognizes soluble, nontoxic amyloid-beta peptide but not aggregated, cytotoxic amyloid-beta peptide. J Biol Chem 271:18032-18044.
6. Bonifácio MJ, Sakaki Y, and Saraiva MJ (1996). "In vitro" amyloid fibril formation from transthyretin: The influence of ions and the amyloidogenicity of TTR variants. Biochim Biophys Acta 1316:35-42.
7. Brett J, Schmidt AM, Zhou YS, Yan SD, Weidman E, Pinsky D, Neeper M, Przysiecki C, Shaw A., Migheli A, and Stern D (1993). Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143:1699-1712.
8. Dignam J, Lebovitz R, and Roeder R (1983). Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11:1475-1489.
9. Du Yan S, Zhu H, Fu J, Yan SF, Roher A, Tourtellotte WW, Rajavashisth T, Chen X, Godman GC, Stern D, and Schmidt AM (1997). Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA 94:5296-5301.
10. Giulian D, Haverkamp L, Li J, Karshin Y, Yu J, Tom D, Li X, and Kirkpatrick J (1995). Senile plaques stimulate microglia to release a neurotoxin found in Alzheimer brain. Neurochem Int 27:119-137.
11. Giulian D, Haverkamp LJ, Yu J, Karshin W, Tom D, Li J, Kazanskaia A, Kirkpatrick J, and Roher AE (1998). The HHQK domain of beta-amyloid provides a structural basis for the immunopathology of Alzheimer's disease. J Biol Chem 273: 29719-29726.
12. Gustavsson A, Jahr H, Tobiassen R, Jacobson DR, Sletten K, and Westermark P (1995). Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis. Lab Invest 73:703-708.
13. Hensley K, Carney J, Mattson M, Aksenova M, Harris M, Wu J, Floyd R, and Butterfield D (1994). A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease. Proc Natl Acad Sci USA 91:3270-3274.
14. Hofmann M, Drury S, Caifeng F, Qu W, Taguchi A, Lu Y, Avila C, Kambhan N, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Nawroth P, Stern D, and Schmidt AM (1999). RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 97: 889-901.
15. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, and Nitecki D (1995). The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270:25752-25761.
16. Kindy M, Hong D, Schmidt AM, Stern D, and Yan SD (1999). Soluble RAGE decreases splenic cellular activation and accumulation in a murine model of systemic amyloidosis. Society for Neuroscience, vol 25 (part II):1566 (abstract).
17. Kislinger T, Fu C, Qu W, Yan S, Hofmann M, Pieschetstrieder M, Stern D, and Schmidt AM (1999). N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740-31749.
18. Klegeris A, Walker D, and McGeer P (1994). Activation of macrophages by Alzheimer beta amyloid peptide. Biochem Biophys Res Commun 199:984-991.
19. Klotz I and Hunston D (1984). Mathematical models for ligand-receptor binding. Real sites, ghost sites. J Biol Chem 259:10060-10062.
20. LaFerla FM, Troncoso JC, Strickland DK, Kawas CH, and Jay G (1997). Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. J Clin Invest 100:310-320.
21. Li J and Schmidt AM (1997). Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 272:16498-16506.
22. Matter M, Zhang Z, Nordstadt C, and Ruoslahti E (1998). The alpha-5 beta-1 integrin receptor binds the Alzheimer disease amyloid-beta protein and mediates its internalization. Keystone Symp Proc X5, 101 (abstract).
23. McGeer P, Kawamata T, Walker D, Akiyama H, Tooyama I, and McGeer E (1993). Microglia in degenerative neurological disease. Glia 7:84-92.
24. 2 microglobulin with human mononuclear phagocytes via an oxidative-sensitive pathway. J Clin Invest 5:1088-1094.
25. Naylor HM and Newcomer ME (1999). The structure of human retinol-binding protein (RBP) with its carrier protein transthyretin reveals an interaction with the carboxy terminus of RBP. Biochemistry 38:2647-2653.
26. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, and Shaw A (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:14998-15004.
27. Quintas A, Saraiva MJ, and Brito RM (1999). The tetrameric protein transthyretin dissociates to a non-native monomer in solution. A novel model for amyloidogenesis. J Biol Chem 274:32943-32949.
28. Raz A, Shiratori T, and Goodman DS (1970). Studies on the protein-protein and protein-ligand interactions involved in retinol transport in plasma. J Biol Chem 245:1903-1912.
29. Saraiva MJ (1995). Transthyretin mutations in health and disease. Hum Mutat 5:191-196.
30. Saraiva MJ, Birken S, Costa PP, and Goodman DS (1983). Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest 74:104-119.
31. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M, Wang F, Pan Y, Tsang T, and Stern D (1992). Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267:14987-14997.
32. Schmidt AM, Hasu M, Popov D, Zhang JH, Chen J, Yan SD, Brett J, Cao R, Kuwabara K, Costache G, Simionescu N, Simionesco M, and Stern SD (1994). Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci USA 91:8807-8811.
33. Schmidt AM, Yan S, Wautier J, and Stern D (1999). Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 84:489-497.
34. Sebastião MP, Saraiva MJ, and Damas AM (1998). The crystal structure of amyloidogenic Leu55 -> Pro transthyretin variant reveals a possible pathway for transthyretin polymerization into amyloid fibrils. J Biol Chem 273:24715-24722.
35. Selkoe DJ (1999). Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399:A23-A31.
36. Shen Y, Yang L-B, Lue L-F, and Rogers J (1998). p55 and p75 TNF receptor subtypes bind amyloid beta-peptide and are differentially expressed in the Alzheimer's brain. Neurobiol Aging 19:S45:#188-S45:#180 (abstract).
37. Sisodia SS and Price DL (1995). Role of the beta-amyloid protein in Alzheimer's disease. FASEB J 9:366-370.
38. Smith M, Perry G, Richey P, Sayre L, Anderson V, Beal M, and Kowall N (1996). Oxidative damage in Alzheimer's. Nature 382:120-121.
39. Yaar M, Zhai S, Pilch PF, Doyle SM, Eisenhauer PB, Fine RE, and Gilchrest BA (1997). Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. J. Clin. Invest. 100:2333-2340.
40. Yan SD, Chen X, Fu J, Chen X, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, and Schmidt AM (1996). RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382:685-691.
41. Yan SD, Yan SF, Chen X, Fu J, Chen M, Kuppusamy P, Smith MA, Perry G, Godman GC, Nawroth P, Zweier JL, and Stern D (1995). Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat Med 1:693-699.
42. Yan SD, Zhu H, Zhu A, Golambek A, Soto C, Roher A, Chaney M, Stern D, and Schmidt AM (1999). RAGE is a signal transduction receptor for beta-sheet fibrils: Receptor dependent promotion of A-beta fibril formation, cell surface binding and cellular activation. Society for Neuroscience, vol 25 (part II):1296 (abstract).